Aquestive Licenses U.S. Libervant Rights to Eton for Up to $47.5M
Aquestive granted Eton exclusive U.S. commercialization rights to Libervant, a diazepam buccal film for acute treatment of seizure clusters, subject to FDA approvals. The agreement includes $10 million upfront and up to $47.5 million in regulatory and commercial milestones.